June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Impact of Anti-vascular Endothelial Growth Factor Therapy on Reading Performance in Age-related Macular Degeneration: A Randomized Controlled Trial.
Author Affiliations & Notes
  • Praveen J Patel
    Moorfields Eye Hospital, NIHR BRC at Moorfields Eye Hospital, London, United Kingdom
  • Gary S Rubin
    Moorfields Eye Hospital, NIHR BRC at Moorfields Eye Hospital, London, United Kingdom
  • Fred Kuanfu Chen
    The University of Western Australia, Perth, WA, Australia
    Lions Eye Institute, Perth, WA, Australia
  • Lyndon da Cruz
    Moorfields Eye Hospital, NIHR BRC at Moorfields Eye Hospital, London, United Kingdom
  • Adnan Tufail
    Moorfields Eye Hospital, NIHR BRC at Moorfields Eye Hospital, London, United Kingdom
  • Footnotes
    Commercial Relationships Praveen Patel, Bayer UK (R), Novartis UK (R); Gary Rubin, None; Fred Chen, Bayer (R), Novartis (R); Lyndon da Cruz, None; Adnan Tufail, Bayer (C), Novartis (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4794. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Praveen J Patel, Gary S Rubin, Fred Kuanfu Chen, Lyndon da Cruz, Adnan Tufail, ; Impact of Anti-vascular Endothelial Growth Factor Therapy on Reading Performance in Age-related Macular Degeneration: A Randomized Controlled Trial.. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4794.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To report the impact of anti-vascular endothelial growth therapy on reading performance in patients with neovascular age-related macular degeneration (nAMD) enrolled in a clinical trial.

Methods: Prospective, multi-centre, double-masked, randomised controlled trial of 131 patients with nAMD in a hospital setting. Patients received intravitreous bevacizumab (n=65) or standard care (n=66) to the study eye with a 6 weekly cycle of assessment. Bevacizumab treatment was 1.25mg/0.05ml given as 3 initial treatments with further retreatment as needed using standardised retreatment criteria and one year (54 week) follow-up. Reading performance was determined during the study using MNREAD charts and was a pre-specified but exploratory analysis.

Results: At the week 54 examination, bevacizumab treated patients had an overall improvement in reading performance while patients randomised to standard care had a decline in reading performance. Bevacizumab treated patients were more likely to improve at least 0.3 logMAR in reading acuity (RA) than the patients receiving standard care (26 [ 40%] versus 6 [9.1%], P < 0.0001). There was also an improvement in the maximum reading speed (MRS) with 18 bevacizumab treated patients (27.7%) improving by 80 words/minute or more compared to 1 patient (1.5%) receiving standard care (P < 0.0001).

Conclusions: Bevacizumab improved the chances of a clinically relevant gain in reading performance in the study population. Given the importance of reading as an activity of daily living and as a goal of rehabilitation in visual impairment, the beneficial effects of bevacizumab therapy are expected to have a favourable impact on performance in reading based activities.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×